Design, power, and interpretation of studies in the standard murine model of ALS

Scott, Sean, Kranz, Janice E., Cole, Jeff, Lincecum, John M., Thompson, Kenneth, Kelly, Nancy, Bostrom, Alan, Theodoss, Jill +4 more·2008·Amyotrophic Lateral Sclerosis
DOI 10.1080/17482960701856300

Cited by (503)

Items 201–300 of 503

  1. CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits
    Fernando G. Vieira, Theo Hatzipetros, Kenneth Thompson, Andy J. Moreno, Joshua D. Kidd, Valerie R. Tassinari, Beth A. Levine, Steven Perrin, Alan Gill · 2017 · IBRO Reports
  2. Effect of Sex on Lifespan, Disease Progression, and the Response to Methionine Sulfoximine in the SOD1 G93A Mouse Model for ALS
    Monica Bame, Patricia A. Pentiak, Richard B. Needleman, William S. A. Brusilow · 2012 · Gender Medicine
  3. Use of biomarkers in ALS drug development and clinical trials
    Nadine Bakkar, Ashley V. Boehringer, Robert P. Bowser · 2014 · Brain Research
  4. Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis
    Guanrong Huang, X Lee, Yuting Bian, Zhaohui Shao, G.-N. Sheng, R. Blake Pepinsky, Sha Mi · 2013 · Cell Death and Disease
  5. Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis
    Sebastiano Giuseppe Crisafulli, Simona Brajkovic, Maria Sara Cipolat Mis, Valeria Parente, Stefania Paola Corti · 2017 · Molecular Neurobiology
  6. Redox Modifier Genes and Pathways in Amyotrophic Lateral Sclerosis
    Barrie J. Carter, Pervin N. Anklesaria, Stephanie H. Choi, John F. Engelhardt · 2009 · Antioxidants and Redox Signaling
  7. The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS
    Ravinder Malik, Helen Meng, Piriya Wongkongkathep, Christian I. Corrales, Niki Sepanj, Ryan Saleh Atlasi, Frank‐Gerrit Klärner, Thomas H. Schrader, Melissa J. Spencer, Joseph A. Loo et al. · 2019 · Journal of Biological Chemistry
  8. Adenylyl Cyclase type 3, a marker of primary cilia, is reduced in primary cell culture and in lumbar spinal cord in situ in G93A SOD1 mice
    Xiaoxing Ma, Randy Peterson, John Turnbull · 2011 · BMC Neuroscience
  9. A brief review of recent Charcot-Marie-Tooth research and priorities
    Sean Ekins, Nadia K. Litterman, Renée J.G. Arnold, Robert W. Burgess, Joel S. Freundlich, Steven James Gray, Joseph J Higgins, Brett C. Langley, Dianna E. Willis, Lucia M. Notterpek et al. · 2015 · F1000Research
  10. Non-Invasive MRI and Spectroscopy of mdx Mice Reveal Temporal Changes in Dystrophic Muscle Imaging and in Energy Deficits
    Christopher R. Heier, Alfredo Daniel Guerron, Alexandru V. Korotcov, Stephen Lin, Heather Gordish‐Dressman, Stanley Thomas Fricke, Raymond W. Sze, Eric P. Hoffman, Paul C. Wang, Kanneboyina Nagaraju · 2014 · PLoS ONE
  11. Reduced VGLUT2 expression increases motor neuron viability in Sod1G93A mice
    Hanna Wootz, Anders Enjin, Åsa Wallén‐Mackenzie, Dan Lindholm, Klas Kullander · 2009 · Neurobiology of Disease
  12. A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis
    Xiaohua Xu, Aleksandar Đenić, Luke R. Jordan, Nathan J. Wittenberg, Arthur E. Warrington, Bharath Wootla, Louisa M. Papke, Laurie J. Zoecklein, Daehan Yoo, Jonah Shaver et al. · 2015 · Disease Models & Mechanisms
  13. Out of Control? Managing Baseline Variability in Experimental Studies with Control Groups
    Paul C. Moser · 2019 · Handbook of experimental pharmacology
  14. Expression profile of pattern recognition receptors in skeletal muscle of SOD1 (G93A) amyotrophic lateral sclerosis (ALS) mice and sporadic ALS patients
    Swen Lehmann, E. Esch, P. Hartmann, Anand Goswami, Stefan Nikolin, Joachim Weis, Cordian Beyer, Sonja Johann · 2018 · Neuropathology and Applied Neurobiology
  15. Light-Activated Dynamic Clamp Using iPSC-Derived Cardiomyocytes
    Bonnie Quach, Trine Krogh‐Madsen, Emilia G. Entcheva, David J. Christini · 2018 · Biophysical Journal
  16. Determining sample size adequacy for animal model studies in nutrition research: limits and ethical challenges of ordinary power calculation procedures
    C. Ricci, J. Baumgartner, L. Malan, C. Smuts · 2020 · International Journal of Food Science and Nutrition
  17. Therapy development for ALS: Lessons learned and path forward
    Veena Lanka, Merit Cudkowicz · 2008 · Amyotrophic Lateral Sclerosis
  18. Inappropriate modeling of chronic and complex disorders: How to reconsider the approach in the context of predictive, preventive and personalized medicine, and translational medicine
    Soroush Seifirad, Vahid Haghpanah · 2019 · The EPMA Journal
  19. The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice
    Diane Ly, Anjila Dongol, Peter Cuthbertson, Thomas V. Guy, Nicholas J. Geraghty, Reece Andrew Sophocleous, Lucia Sin, Bradley J. Turner, Debbie Watson, Justin J. Yerbury et al. · 2020 · Purinergic Signalling
  20. Relevance of transgenic mouse models for Alzheimer's disease
    Leon M. Tai, Juan Maldonado Weng, Mary Jo LaDu, Scott T. Brady · 2020 · Progress in molecular biology and translational science
  21. Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP‐43 pathology
    Barış Genç, Mukesh Gautam, Öge Gözütok, Ina Dervishi, Santana S. Sanchez, Gashaw M. Goshu, Nuran Koçak, Edward F. Xie, Richard B. Silverman, P. Hande Özdi̇nler · 2021 · Clinical and Translational Medicine
  22. Riluzole does not ameliorate disease caused by cytoplasmic TDP‐43 in a mouse model of amyotrophic lateral sclerosis
    Amanda L. Wright, Paul A. Della Gatta, Sheng Le, Britt A. Berning, Prachi M. Mehta, Kelly R. Jacobs, Hossai Gul, Rebecca San Gil, Thomas J. Hedl, Winonah R. Riddell et al. · 2021 · European Journal of Neuroscience
  23. Human Pluripotent Stem Cells: Applications and Challenges in Neurological Diseases
    Youssef Hibaoui, Anis Féki · 2012 · Frontiers in Physiology
  24. Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice
    Marco Peviani, Ilaria Caron, Chiara Pizzasegola, Francesco Gensano, Massimo Tortarolo, Caterina Bendotti · 2010 · CNS & Neurological Disorders - Drug Targets
  25. Questions regarding the predictive value of one evolved complex adaptive system for a second: Exemplified by the SOD1 mouse
    Ray Greek, Lawrence A. Hansen · 2013 · Progress in Biophysics and Molecular Biology
  26. Microglia RAGE exacerbates the progression of neurodegeneration within the SOD1G93A murine model of amyotrophic lateral sclerosis in a sex-dependent manner
    MacLean, Michael, Juranek, Judyta, Cuddapah, Swetha, López-Díez, Raquel, Ruiz, Henry H., Hu, Jiyuan, Frye, Laura, Li, Huilin, Gugger, Paul F., Schmidt, Ann Marie · 2021 · Journal of Neuroinflammation
  27. Modeling Amyotrophic Lateral Sclerosis in hSOD1G93A Transgenic Swine
    Maria Novella Chieppa, Andrea Perota, Cristiano Corona, Anna Grindatto, Irina Lagutina, Elena Vallino Costassa, Giovanna Lazzari, S. Colleoni, Roberto Duchi, Franco Lucchini et al. · 2013 · Neurodegenerative Diseases
  28. Androgen receptor antagonism accelerates disease onset in the SOD1 G93A mouse model of amyotrophic lateral sclerosis
    Victoria M. McLeod, Chew Ling Lau, Mathew D. F. Chiam, Thusitha Rupasinghe, Ute Roessner, Elvan Djouma, Wah Chin Boon, Bradley J. Turner · 2019 · British Journal of Pharmacology
  29. The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS
    Yulia Dzhashiashvili, Chase P. Monckton, Harini Shah, Rejani B. Kunjamma, Brian Popko · 2019 · Neurobiology of Disease
  30. Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis
    Arpan R. Mehta, Rachel Walters, Fergal M. Waldron, Suvankar Pal, Bhuvaneish Thangaraj Selvaraj, Malcolm Robert Macleod, Giles E. Hardingham, Siddharthan Chandran, Jenna M. Gregory · 2019 · Brain Communications
  31. Mitochondria: A Promising Convergent Target for the Treatment of Amyotrophic Lateral Sclerosis
    Teresa Cunha‐Oliveira, Liliana Montezinho, Rui F. Simões, Marcelo de Carvalho, Elisabete B. Ferreiro, Filomena S. G. Silva · 2024 · Cells
  32. Moving forward in clinical trials for ALS: motor neurons lead the way please
    Barış Genç, P. Hande Özdi̇nler · 2013 · Drug Discovery Today
  33. Transplantation of mesenchymal stem cells in ALS
    Letizia Mazzini, Alessandro Vercelli, Ivana Ferrero, Marina Boido, Roberto M. Cantello, Franca Fagioli · 2012 · Progress in brain research
  34. Association of ROP18 and ROP5 was efficient as a marker of virulence in atypical isolates of Toxoplasma gondii obtained from pigs and goats in Piauí, Brazil
    Wagner Martins Fontes do Rêgo, Jean-Marc Costa, Ramon Castro de Araújo Baraviera, Lorena Velozo Pinto, Gabriella de Lima Bessa, Rosálida Estevam Nazar Lopes, Ricardo Wagner Almeida Vítor · 2017 · Veterinary Parasitology
  35. Modelling amyotrophic lateral sclerosis in mice
    Jodie Stephenson, Sandra Amor · 2017 · Drug Discovery Today Disease Models
  36. Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond
    Sara Nikseresht, James B. W. Hilton, Kai Kysenius, Jeffrey R. Liddell, Peter John Crouch · 2020 · Life
  37. Does the preclinical evidence for functional remyelination following myelinating cell engraftment into the injured spinal cord support progression to clinical trials?
    Scott A. Myers, Andrew N. Bankston, Darlene A. Burke, Sujata Saraswat Ohri, Scott R. Whittemore · 2016 · Experimental Neurology
  38. Why Are So Many Epidemiology Associations Inflated or Wrong? Does Poorly Conducted Animal Research Suggest Implausible Hypotheses?
    Michael B. Bracken · 2009 · Annals of Epidemiology
  39. Dietary Supplementation with S-Adenosyl Methionine Delays the Onset of Motor Neuron Pathology in a Murine Model of Amyotrophic Lateral Sclerosis
    James J. Suchy, Sangmook Lee, Ambar Ahmed, Thomas B. Shea · 2009 · NeuroMolecular Medicine
  40. Status of ALS treatment, insights into therapeutic challenges and dilemmas
    Khamaysa, Mohammed, Pradat, Pierre-François · 2022 · Journal of Personalized Medicine
  41. Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol
    Manoj Mathew Lalu, Joshua Ryan Montroy, C. Glenn Begley, Tania M. Bubela, Victoria T. Hunniford, David Ripsman, Neil L. Wesch, Jonathan Kimmelman, Malcolm Robert Macleod, David Moher et al. · 2020 · F1000Research
  42. Glutamatergic Neuroplasticity in Cocaine Addiction
    Joachim D. K. Uys, Kathryn J. Reissner · 2011 · Progress in molecular biology and translational science
  43. Regulation of Intracellular Copper by Induction of Endogenous Metallothioneins Improves the Disease Course in a Mouse Model of Amyotrophic Lateral Sclerosis
    Eiichi Tokuda, Shunsuke Watanabe, Eriko Okawa, Shin-ichi Ono · 2015 · Neurotherapeutics
  44. Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders
    Rodney Lee Mosley, Howard Eliot Gendelman · 2010 · Experimental Neurology
  45. Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross‐sectional study
    Holger Langhof, W. W. Chin, S. Wieschowski, Carole A. Federico, J. Kimmelman, D. Strech · 2018 · British Journal of Pharmacology
  46. TRICALS: creating a highway toward a cure
    Ruben P. A. van Eijk, Tessa Kliest, Christopher J. McDermott, Kit C. B. Roes, Philip Van Damme, Adriano Chiò, Markus Weber, Caroline Ingre, Philippe Corcia, Mónica Povedano et al. · 2020 · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  47. Adipose-derived stem cells protect motor neurons and reduce glial activation in both in vitro and in vivo models of ALS
    Yuri Ciervo, Noemi Gatto, Chloe F. Allen, Andrew J. Grierson, Laura Ferraiuolo, Richard J. Mead, Pamela J. Shaw · 2021 · Molecular Therapy — Methods & Clinical Development
  48. How significant are your data? The need for a culture shift
    Martin Christian Michel · 2014 · Naunyn-Schmiedeberg s Archives of Pharmacology
  49. Pathophysiology, Clinical Heterogeneity, and Therapeutic Advances in Amyotrophic Lateral Sclerosis: A Comprehensive Review of Molecular Mechanisms, Diagnostic Challenges, and Multidisciplinary Management Strategies
    María González-Sánchez, Marı́a Jesús Ramı́rez-Expósito, José Manuel Martı́nez-Martos · 2025 · Life
  50. Preclinical Evidence for the Efficacy of Ischemic Postconditioning against Renal Ischemia-Reperfusion Injury, a Systematic Review and Meta-Analysis
    Simone J. Jonker, Theo P. Menting, Michiel C. Warlé, Merel J. Ritskes-Hoitinga, Kimberley Elaine Wever · 2016 · PLoS ONE
  51. Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis
    John D. Lee, Ning Liu, Samantha C. Levin, Lars Ottosson, Ulf Andersson, Helena Erlandsson Harris, Trent M. Woodruff · 2019 · Journal of Neuroinflammation
  52. The methodological quality of animal research in critical care: the public face of science
    Meredith Bara, Ari Robin Joffe · 2014 · Annals of Intensive Care
  53. Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity?
    Renzo Mancuso, Jaume del Valle, Marta Morell, Mercè Pallàs, Rosario Osta, Xavier Navarro · 2014 · Orphanet Journal of Rare Diseases
  54. Focus on the Role of D-serine and D-amino Acid Oxidase in Amyotrophic Lateral Sclerosis/Motor Neuron Disease (ALS)
    Nazanin Rahmani Kondori, Praveen Paul, Jacqueline P. Robbins, Ke Liu, John C. W. Hildyard, Dominic J. Wells, Jacqueline de Belleroche · 2018 · Frontiers in Molecular Biosciences
  55. Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT)
    Raffaella Willmann, Joanne Lee, Cathy Turner, Kanneboyina Nagaraju, Annemieke M Aartsma-Rus, Dominic J. Wells, Kathryn R. Wagner, Cristina Csimma, Volker W. Straub, Miranda D. Grounds et al. · 2020 · Disease Models & Mechanisms
  56. Mouse Models of Neurodegenerative Diseases: Criteria and General Methodology
    Christopher Janus, Hans Welzl · 2009 · Methods in molecular biology
  57. Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity
    Stefanie Saenger, Bettina Holtmann, Mark R. Nilges, Susanne Schroeder, Andreas Hoeflich, Heidemarie Kletzl, Will P. J. M. Spooren, Susanne Ostrowitzki, Taleen Hanania, Michael Sendtner et al. · 2012 · Amyotrophic Lateral Sclerosis
  58. Yeast genetic screen reveals novel therapeutic strategy for ALS
    Matthew D. Figley, Aaron D. Gitler · 2013 · Rare Diseases
  59. Axonal and neuromuscular synaptic phenotypes in Wld, SOD1 and ostes mutant mice identified by fiber-optic confocal microendoscopy
    Frances Wong, Li Fan, Sara E. Wells, Robert Hartley, Francesca E. Mackenzie, Oyinlola O Oyebode, Rosalind Brown, Derek Thomson, Michael P. Coleman, Gonzalo Blanco et al. · 2009 · Molecular and Cellular Neuroscience
  60. Amyotrophic Lateral Sclerosis: Drug Therapy from the Bench to the Bedside
    Mark B. Bromberg, Summer B. Gibson · 2012 · Seminars in Neurology
  61. Epothilone D accelerates disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis
    Jayden A. Clark, Catherine A. Blizzard, Monique C. Breslin, Elise J. Yeaman, K. M. Lee, Jyoti A. Chuckowree, Tracey C. Dickson · 2018 · Neuropathology and Applied Neurobiology
  62. Review: Microglia in motor neuron disease
    Bridget Ashford, Delphine Boche, Johnathan Cooper‐Knock, Paul Roy Heath, Julie E. Simpson, J. Robin Highley · 2020 · Neuropathology and Applied Neurobiology
  63. Preclinical Stroke Research and Translational Failure: A Bird’s Eye View on Preventable Variables
    Devendra Singh, Himika Wasan, K.H. Reeta · 2021 · Cellular and Molecular Neurobiology
  64. Food restriction-induced autophagy modulates degradation of mutant SOD1 in an amyotrophic lateral sclerosis mouse model
    Kunxi Zhang, Pengxiao Shi, Ting An, Qian Wang, Jingjing Wang, Zhongyao Li, Weisong Duan, Chunyan Li, Yansu Guo · 2013 · Brain Research
  65. Intraspinal bone-marrow cell therapy at pre- and symptomatic phases in a mouse model of amyotrophic lateral sclerosis
    Fernanda Gubert, Ana B. Decotelli, Igor Bonacossa-Pereira, Fernanda R. Figueiredo, Camila Zaverucha-do-Valle, Fernanda Freire Tovar-Moll, Luísa Hoffmann, Turán Peter Urmenyi, Marcelo F. Santiago, Rosalia Méndez‐Otero · 2016 · Stem Cell Research & Therapy
  66. Gene therapy for amyotrophic lateral sclerosis
    Thais Federici, Nicholas M. Boulis · 2011 · Neurobiology of Disease
  67. Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy
    Christopher R. Bye, Elizabeth Ling Qian, Katherine Lim, Maciej Daniszewski, Fleur C. Garton, Bảo C. Trần-Lê, Helena Hai Liang, Tian Lin, John George Lock, Duncan E. Crombie et al. · 2025 · Nature Neuroscience
  68. Lacking quality in research: Is behavioral neuroscience affected more than other areas of biomedical science?
    Anton Bespalov, Thomas Steckler · 2017 · Journal of Neuroscience Methods
  69. Genetic diversity of Toxoplasma gondii isolates obtained from free-living wild birds rescued in Southeastern Brazil
    Wagner Martins Fontes do Rêgo, Jean-Marc Costa, Ramon Castro de Araújo Baraviera, Lorena Velozo Pinto, Gabriella de Lima Bessa, Rosálida Estevam Nazar Lopes, Júlia Angélica Gonçalves da Silveira, Ricardo Wagner Almeida Vítor · 2018 · International Journal for Parasitology Parasites and Wildlife
  70. Dendrimer-2PMPA Delays Muscle Function Loss and Denervation in a Murine Model of Amyotrophic Lateral Sclerosis
    Carolyn Tallon, Anjali Sharma, Zhi Zhang, Ajit G. Thomas, Justin Ng, Xiaolei Zhu, Amanda Donoghue, Michael I. Schulte, Tawnjerae R. Joe, Siva P. Kambhampati et al. · 2022 · Neurotherapeutics
  71. Advances in Cellular Models to Explore the Pathophysiology of Amyotrophic Lateral Sclerosis
    Charlotte Veyrat‐Durebex, Philippe Corcia, Audrey Dangoumau, Frédéric Laumonnier, Éric Piver, P. H. Gordon, Christian Robert Andres, Patrick Vourc’h, Hélène Blasco · 2013 · Molecular Neurobiology
  72. Improving the predictive value of interventional animal models data
    Caroline J. Zeiss · 2014 · Drug Discovery Today
  73. Dexpramipexole Is Ineffective in Two Models of ALS Related Neurodegeneration
    Fernando G. Vieira, Eva LaDow, Andy J. Moreno, Joshua D. Kidd, Beth A. Levine, Kenneth Thompson, Alan Gill, Steven M. Finkbeiner, Steven Perrin · 2014 · PLoS ONE
  74. The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials
    Spencer Phillips Hey, Jonathan Kimmelman · 2014 · Kennedy Institute of Ethics journal
  75. In Vivo Fiber Optic Raman Spectroscopy of Muscle in Preclinical Models of Amyotrophic Lateral Sclerosis and Duchenne Muscular Dystrophy
    Maria Plesia, Oliver A. C. Stevens, Gavin Rhys Lloyd, Catherine A. Kendall, Ian Coldicott, Aneurin J. Kennerley, Gaynor Miller, Pamela J. Shaw, Richard J. Mead, John C. C. Day et al. · 2021 · ACS Chemical Neuroscience
  76. The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS
    Amy F. A. Keerie, Heledd Brown-Wright, Isaac Kirkland, Andrew J. Grierson, James J. P. Alix, Christian Hölscher, Richard J. Mead · 2021 · Scientific Reports
  77. Closed Testing in Pharmaceutical Research: Historical and Recent Developments
    Kevin S. S. Henning, Peter H. Westfall · 2015 · Statistics in Biopharmaceutical Research
  78. First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models
    Julie Kelly, Noreen T. Boyle, Natalie Cole, Gillian R. Slator, Maria Alessandra Colivicchi, Chiara Stefanini, Oliviero L. Gobbo, Gaia Scalabrino, Sinéad M. Ryan, Marwa Elamin et al. · 2014 · Neuropharmacology
  79. Amyotrophic lateral sclerosis: current practice and future treatments
    Richard Bedlack · 2010 · Current Opinion in Neurology
  80. Reduction in hSOD1 copy number significantly impacts ALS phenotype presentation in G37R (line 29) mice: implications for the assessment of putative therapeutic agents
    Pierre Zwiegers, Grace Lee, Christopher A. Shaw · 2014 · Journal of Negative Results in BioMedicine
  81. Evidence-based translational medicine.
    D. Howells, M. Macleod · 2013 · Stroke
  82. Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms
    Rebecca M. Pruss · 2010 · CNS & Neurological Disorders - Drug Targets
  83. Experimental Design and Data Analysis Issues Contribute to Inconsistent Results of C-Bouton Changes in Amyotrophic Lateral Sclerosis
    Saihari S. Dukkipati, Aouatef Chihi, Yiwen Wang, Sherif M. Elbasiouny · 2017 · eNeuro
  84. Murine models of polycystic kidney disease
    Luís F. Menezes, Gregory George Germino · 2013 · Drug Discovery Today Disease Mechanisms
  85. The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development
    Emma Heslop, Cristina Csimma, Volker W. Straub, John McCall, Kanneboyina Nagaraju, Kathryn R. Wagner, Didier Caizergues, Rudolf Korinthenberg, Kevin M. Flanigan, Petra Kaufmann et al. · 2015 · Orphanet Journal of Rare Diseases
  86. Evaluation of taurine neuroprotection in aged rats with traumatic brain injury
    Raeesa Gupte, Sarah K. Christian, Paul Keselman, Joshua Habiger, William Miles Brooks, Janna L. Harris · 2018 · Brain Imaging and Behavior
  87. Human Induced Pluripotent Stem Cell-Derived TDP-43 Mutant Neurons Exhibit Consistent Functional Phenotypes Across Multiple Gene Edited Lines Despite Transcriptomic and Splicing Discrepancies
    Alec S.T. Smith, Changho Chun, Jennifer Hesson, Julie Mathieu, Paul N. Valdmanis, David L. Mack, Byung‐Ok Choi, Deok‐Ho Kim, Mark A. Bothwell · 2021 · Frontiers in Cell and Developmental Biology
  88. Intraretinal calcium channels and retinal morbidity in experimental retinopathy of prematurity.
    Bruce A. Berkowitz, David Bissig, Deborah Bergman, Emanuela Bercea, Vijaya K. Kasturi, Robin Roberts · 2011 · Europe PMC (PubMed Central)
  89. Preclinical assessment for translation to humans: The PATH approach for assessing supporting evidence for early-phase trials and innovative care
    Jonathan Kimmelman, Patrick Bodilly Kane, Selin Bicer, Benjamin Gregory Carlisle · 2024 · Med
  90. Genetically Defined Strains in Drug Development and Toxicity Testing
    Michael F. W. Festing · 2016 · Methods in molecular biology
  91. A Cystine-Rich Whey Supplement (Immunocal®) Delays Disease Onset and Prevents Spinal Cord Glutathione Depletion in the hSOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis
    Erika Ross, Aimee N. Winter, Heather Wilkins, Whitney Sumner, Nathan Duval, David Patterson, Daniel A. Linseman · 2014 · Antioxidants
  92. All-Trans Retinoic Acid Exerts Neuroprotective Effects in Amyotrophic Lateral Sclerosis-Like Tg (SOD1*G93A)1Gur Mice
    Yu Zhu, Yue Liu, Fang Yang, Wenzhi Chen, Jianxian Jiang, Pei He, Shishi Jiang, Menhua Li, Renshi Xu · 2020 · Molecular Neurobiology
  93. qMotor, a set of rules for sensitive, robust and quantitative measurement of motor performance in mice
    Laura Martina Luh, Indrajit Das, Anne Bertolotti · 2016 · Nature Protocols
  94. Galectin‐1 deficiency improves axonal swelling of motor neurones in SOD 1G93A transgenic mice
    Yuko Kobayakawa, Kunihiko Sakumi, Kosuke Kajitani, Toshihiko Kadoya, Hidenori Horie, Jun‐ichi Kira, Yusaku Nakabeppu · 2014 · Neuropathology and Applied Neurobiology
  95. Lack of Effect of Methylene Blue in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis
    Rosamond Lougheed, John Turnbull · 2011 · PLoS ONE
  96. Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
    René Günther, Martin Suhr, Jan Christoph Koch, Mathias Bähr, Paul Lingor, Lars Tönges · 2012 · Journal of Visualized Experiments
  97. MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis
    Kelly E. Glajch, Laura Ferraiuolo, Kaly A. Mueller, Matthew J. Stopford, Varsha Prabhkar, Achille Gravanis, Pamela J. Shaw, Ghazaleh Sadri‐Vakili · 2016 · PLoS ONE
  98. BJP is changing its requirements for scientific papers to increase transparency
    John Christie McGrath, Michael J. Curtis · 2015 · British Journal of Pharmacology
  99. Translational science: a survey of US biomedical researchers’ perspectives and practices
    Rebecca L. Walker, Katherine Witte Saylor, Margaret Waltz, Jill A. Fisher · 2021 · Lab Animal
  100. Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models
    Martina Milani, Ilaria Della Valle, Simona Rossi, Paola Fabbrizio, Cassandra Margotta, Giovanni Nardo, Mauro Cozzolino, Nadia D’Ambrosi, Savina Apolloni · 2024 · Neurotherapeutics